Document:

Exhibit 10.19

		

			EXECUTION COPY

		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			PARKERVISION, INC.
		

		
			 
		

		
			– and –
		

		
			 
		

		
			1624 PV LLC
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			___________________________________________
		

		
			 
		

		
			 
		

		
			FUNDING AGREEMENT
		

		
			 
		

		
			___________________________________________
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		

		

		 

		

			 

		

		

			 

		

		

			

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

		PARKERVISION ENFORCEMENT FUNDING AGREEMENT
		

		
			This PARKERVISION ENFORCEMENT FUNDING AGREEMENT (the “Agreement”) is made and entered into as of December 23, 2014 (the “Effective Date”) by and between ParkerVision, Inc., a corporation existing under the laws of Florida (“ParkerVision” or the “Company”) and 1624 PV LLC, a Delaware limited liability company (the “Funder”) (each a “Party”).
		

		
			WHEREAS, the Company requires funding for patent Enforcement (as defined below); and
		

		
			WHEREAS, the Funder is willing to provide such funding in exchange for consideration;
		

		
			NOW, THEREFORE, in consideration of the promises and of the mutual covenants and promises hereinafter set forth, the parties to this Agreement do hereby agree as follows:
		

		
			1.DEFINITIONS
		

		
			 
		

		
			1.1“ADVERSE COSTS” means Company’s obligation and/or liability, through any order of a court and/or settlement or otherwise, requiring the Company and/or Funder to pay some or all of the costs including without limitation legal fees, disbursements, or court fees, of another party to an Enforcement. 
		

		
			 
		

		
			1.2“AFFILIATE” means (a) any Person directly or indirectly controlling, controlled by or under common control with, another Person, (b) any Person owning or controlling 50% or more of the outstanding voting securities of such other Person, or (c) any officer, director or equityholder of such Person.
		

		
			 
		

		
			1.3“AGREEMENT” means this Agreement, as amended, modified or supplemented from time to time.
		

		
			 
		

		
			1.4“APPEAL” means an appeal by Company or one or more Initial Targets regarding the decision of a lower court related to Enforcements brought by the Company against Initial Targets.
		

		
			 
		

		
			1.5“ATTORNEY” means Company’s legal representation, including [*] and/or patents attorneys employed in furtherance of the Enforcement brought by the Company against Initial Targets.
		

		
			 
		

		
			1.6“BANKRUPTCY” means Title 11, U.S. Code or any similar federal or state law for the relief of debtors, as amended, and all rules and regulations promulgated thereunder.
		

		
			 
		

		
			1.7“CODE” means the Internal Revenue Code of 1986, as amended from time to time.
		

		
			 
		

		

		

		 

		

			1

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

		1.8“COMMITTED CAPITAL” means the total maximum amount available to fund the Enforcement under this Agreement as itemized in Schedule A and subject to changes permitted by this Agreement.
		

		
			1.9“CONDITIONAL FEE” means a portion of the Enforcement Proceeds, as set forth in the retainer agreement between Patent Holder and Attorney, which agreement is being attached as Appendix B.
		

		
			1.10CONFIDENTIAL INFORMATION” has the meaning given such term in Section 11.1.1.
		

		
			 
		

		
			1.11[*] 
		

		
			1.12“DISBURSEMENTS” means costs, other than Legal Fees, typically associated with an Enforcement including reports, attorney travel expenses, consultant and/or expert fees, court fees (except as otherwise noted herein), trial graphics, document services, and production costs.
		

		
			 
		

		
			1.13“DISCLOSEES” has the meaning given such term in Section 11.1.1. 
		

		
			 
		

		
			1.14“ENFORCEMENT” means any and all proceeding(s) or negotiation(s), whether or not before a court or judicial body, where the Company seeks monetary or non-monetary compensation for and/or on behalf of the Patents, including any post grant review or re-examination of any of the Patents initiated by one or more Targets.
		

		
			1.15“ENFORCEMENT PLAN” has the meaning given such term in Schedule A.
		

		
			 
		

		
			1.16“ENFORCEMENT PROCEEDS” means the gross aggregate total revenues and/or proceeds, whether monetary or non-monetary, earned in relation to or in connection with the Enforcements,  [*] and all similar sums, in each case, received by or on behalf of Company after the Effective Date, before deduction of any taxes.
		

		
			 
		

		
			1.17“EXISTING ENFORCEMENT” means the two litigations pending as of the Effective Date between (i) the Company and Qualcomm, Inc. (Case No. 2014-1612) and (ii) the Company and Qualcomm, Inc., et al. (Case No. 6:14-cb-00687).
		

		
			 
		

		
			1.18“EXCLUDED EXPENSES” means any costs, sums or liabilities other than those set forth in Schedule A, including without limitation:
		

		
			 
		

		
			1.18.1Legal costs and/or other sums incurred as a result of Company’s failure to cooperate with or follow the reasonable advice of the Attorney;
		

		
			 
		

		
			1.18.2Liability for costs arising in the form of Company’s or Attorney’s liability for court-ordered penalties, fines or sanctions;
		

		
			 
		

		

		

		 

		

			2

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

		1.18.3Legal costs and/or other sums incurred in the form of Company’s or Attorney’s liability for court-ordered penalties, fines or sanctions as a result of any unreasonable failure by the Company or the Attorney to comply with [*] or an order of the court during any Enforcement;
		

		
			 
		

		
			1.18.4Legal costs and/or other sums incurred in the form of Company’s liability for court-ordered penalties, fines or sanctions as a result of any unreasonable failure by Company to comply with a [*];
		

		
			 
		

		
			1.18.5Any expenses related to an Existing Enforcement;
		

		
			 
		

		
			1.18.6Legal costs incurred in excess of the Committed Capital;
		

		
			 
		

		
			1.18.7Any Adverse Costs obligation and/or liability;
		

		
			1.18.8Any element of [*] where otherwise recoverable by the Company;  and
		

		
			 
		

		
			1.18.9Any legal costs and expenses incurred prior to the date of this Agreement unless agreed to by both Funder and Company.
		

		
			 
		

		
			1.19“FUNDER” has the meaning given such term in the first paragraph of this Agreement.
		

		
			 
		

		
			1.20“FUNDER’S COMPENSATION”  has the meaning given such term in Schedule A.
		

		
			 
		

		
			1.21“HOLDOVER” has the meaning given such term in Schedule A.
		

		
			 
		

		
			1.22“HOLDOVER INSTRUCTIONS” has the meaning given such term in Schedule A.
		

		
			1.23“INITIAL TARGETS” has the meaning given such term in Schedule A.
		

		
			 
		

		
			1.24“INSURANCE” means an insurance policy covering Adverse Costs, entered into between the Company and Insurer in a form reasonably acceptable to the Funder.
		

		
			 
		

		
			1.25“INSURER” means a provider of Insurance.
		

		
			1.26“LEGAL FEES” means the fees due from the Company to the Attorney in furtherance of an Enforcement.
		

		
			 
		

		
			1.27“PARTY” has the meaning given such term in the first paragraph of this Agreement.
		

		
			 
		

		
			1.28“PATENTS” has the meaning given such term in Schedule A.
		

		
			 
		

		 

		

			3

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

		
			1.29“PERSON” means (a) a person as that term is defined in Section 7701(a)(1) of the Code, namely, an individual, trust, estate, partnership, association, company or corporation, and (b) those persons who are related by blood or marriage to a person defined in (a) above.  
		

		
			 
		

		
			1.30“PRIORITY” has the meaning given such term in Appendix A. 
		

		
			 
		

		
			1.31“REGULATIONS” means the Income Tax Regulations promulgated under the Code, as such regulations may be amended from time to time (including corresponding provisions of succeeding regulations).  
		

		
			 
		

		
			1.32“REIMBURSEMENT AMOUNT” has the meaning given such term in Schedule A.
		

		
			 
		

		
			1.33“RELEASE REQUEST” has the meaning given such term in Section 2.2.3.
		

		
			 
		

		
			1.34“RELEASED FUNDING” means the amounts actually released pursuant to this Agreement.
		

		
			 
		

		
			1.35“RELEVANT INFORMATION” has the meaning given such term in Section 10.9.
		

		
			1.36“RETAINER AGREEMENT” means the representation agreement between Company and Attorney, as set forth in Exhibit B.
		

		
			1.37“SECURITIES LAWS” means federal and state securities laws and stock exchange rules applicable to Company, including without limitation the Securities Exchange Act of 1934, as amended. 
		

		
			1.38 “SECTION” means the designated section of this Agreement if no reference is specified; otherwise the designated section of the specified agreement, statute or regulation or the comparable provision of any successor agreement, statute or regulation.  
		

		
			1.39“SUBSEQUENT TARGETS” has the meaning given such term in Schedule A.
		

		
			1.40“SUBSEQUENT ENFORCEMENTS” has the meaning given such term in Schedule A.
		

		
			1.41“TARGETS” means any and all parties alleged to be infringing the Patents against whom Company is pursuing legal action and/or against and/or with whom Company seeks to monetize and/or commercialize the Patents.
		

		
			1.42“YEAR” means the calendar year, except for the initial and final Year of the Agreement which may begin or end on a date other than January 1 and December 31, respectively.  
		

		
			 
		

		 

		

			4

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

		
			2.OBLIGATIONS OF THE PARTIES
		

		
			 
		

		
			2.1OBLIGATIONS OF THE COMPANY.    The Company shall (a) use reasonable commercial efforts to execute the Enforcement Plan involving the Initial Targets set forth in Schedule A hereto, (b) perform its other obligations in all material respects pursuant to this Agreement, (c) pay to the Funder the Funder’s Compensation as set forth in Schedule A, and otherwise (d) distribute Enforcement Proceeds pursuant to Schedule A.
		

		
			 
		

		
			2.1.1Where  any Enforcement,  whether by way of court order, settlement or otherwise, gives rise to the receipt by the Company of Enforcement Proceeds not subject to an appeal or recapture, the Company undertakes to the Funder to pay to the Funder the Funder’s Compensation in accordance with Schedule A, and
		

		
			 
		

		
			2.1.1.1With respect to Enforcement Proceeds from Initial Targets, Company shall instruct the Attorneys:
		

		
			 
		

		
			2.1.1.1.1to receive such Enforcement Proceeds on its behalf and to notify counsel for the Target(s) that the Attorneys are authorized to receive such proceeds; 
		

		
			2.1.1.1.2to immediately pay such Enforcement Proceeds into a designated account;
		

		
			2.1.1.1.3to contact Funder, notify Funder of the amounts of such Enforcement Proceeds and receive joint instruction from Funder and the Company as to the distribution of such Enforcement Proceeds;
		

		
			2.1.1.1.4to distribute the Funder’s Compensation to the Funder within ten (10) Business Days of receiving distribution instructions pursuant to this Section; and
		

		
			2.1.1.1.5to keep in the designated account the Holdovers and pay them out in accordance with the Holdover Instructions.
		

		
			 
		

		
			2.1.1.2Where the Company receives directly any or all of Enforcement Proceeds from Initial Targets, it undertakes to pay all the same, immediately on receipt, to the Attorneys to be deposited, distributed and/or held in the matter set forth in Section 2.1.1.1.
		

		
			 
		

		
			2.1.2The obligations created herein are continuing obligations and survive any termination of this Agreement.
		

		
			 
		

		
			2.1.3Company shall distribute Enforcement Proceeds from Initial Targets in accordance with the Priority as set forth in Appendix  A.
		

		 

		

			5

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

		
			 
		

		
			2.2OBLIGATIONS OF THE FUNDER.  The Funder agrees to fund up to the Committed Capital on the following terms:
		

		
			 
		

		
			2.2.1The Funder shall fund Legal Fees and Disbursements, if and as approved in advance in writing by the Company, up to the Committed Capital as described in Schedule A;
		

		
			 
		

		
			2.2.2The funds shall be released to the Attorney in accordance with this Agreement subject to the advance written approval of the Company and any review by the Funder on the occurrence of an event set forth in Section 2.2.3;
		

		
			 
		

		
			2.2.3The Attorney may request a release of funds by delivering a written request to the Funder (a “Release Request”).  Each Release Request shall be accompanied by all relevant invoice(s) and the written approval of the Company. The amount requested shall not exceed the amount of fees and disbursements stated on said invoice(s).  Subject to the provisions of Section 4, within thirty (30) days of receipt of a complete and accurate Release Request, Funder shall pay the amount requested into the Attorney’s designated account. 
		

		
			 
		

		
			2.2.4The Funder shall not be liable under this Agreement for any Excluded Expenses incurred by the Company.
		

		
			 
		

		
			2.2.5The Company may itself fund Legal Fees and Disbursements without the use of Committed Capital.
		

		
			 
		

		
			2.3ADDITIONAL FUNDING BY THE FUNDER; APPEALS.
		

		
			 
		

		
			2.3.1If the Company should require funds in excess of the Committed Capital for the pursuit of the Enforcements involving Initial Targets, including an Appeal, the Company reaffirms and agrees that Funder has the right, at its discretion, to provide additional funds for such Enforcement or to fund any Appeal.
		

		
			 
		

		
			2.3.2If Funder elects to provide additional funds for any Enforcement or Appeal involving Initial Targets,  Company agrees to instruct the Attorneys to act on such Enforcement or Appeal, and the Parties shall enter into a new funding agreement in respect of such additional funding unless Funder agrees to increase the Committed Capital under this Agreement.
		

		
			 
		

		
			2.3.3If Funder elects not to provide additional funds for any Enforcement or Appeal involving Initial Targets:
		

		
			 
		

		 

		

			6

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

		
			2.3.3.1Company undertakes to Funder that it shall not, without the prior written consent of Funder, make any payments out of Enforcement Proceeds received by or on behalf of Company in connection with such Enforcement or Appeal prior to the Enforcement or Appeal being concluded;
		

		
			 
		

		
			2.3.3.2Company shall be entitled to obtain funding from an alternative source [*].
		

		
			 
		

		
			2.INTERESTS AND RIGHTS IN SUBSEQUENT ENFORCEMENTS
		

		
			 
		

		
			2.1.Funder shall have the rights concerning Subsequent Enforcements, including rights to Enforcement Proceeds, set forth in Schedule A.
		

		
			 
		

		
			3.SETTLEMENT OF THE ENFORCEMENT
		

		
			 
		

		
			3.1.Company shall not make or accept an offer of partial or full settlement in any Enforcement involving Initial Targets or discontinue or make any material concession in any such Enforcement without prior notification to the Funder. For the sake of clarity, the Parties agree that pursuant to Section 15.12,  infra, the ultimate decision to make and accept any offers of partial or full settlement in any Enforcement involving Initial Targets and to discontinue or make any material concessions in any such Enforcement rests solely with Company and its Attorney, and that Funder has no right to reject or veto such decisions.   
		

		
			 
		

		
			4.TERMINATION OF THIS AGREEMENT
		

		
			 
		

		
			4.1.Company may terminate this Agreement upon at least thirty (30)  days’ prior written notice to Funder if Funder has failed to perform its obligations under Section 2.2 in all material respects.
		

		
			 
		

		
			4.2.Funder may terminate this Agreement upon at least fourteen (14) days’ prior written notice to Company in any of the following cases:
		

		
			 
		

		
			4.2.1.Circumstances have arisen since the commencement of an Enforcement involving an Initial Target which cause Funder to have a good faith basis to believe that such Enforcement lacks merit and/or commercial viability, such as, by way of example and not limitation, where such belief is based upon a theory of invalidity or non-infringement of the asserted Patents presented by one or more of the Initial Targets and such theory is plainly supported by admissible evidence; a dispositive ruling of either non-infringement or invalidity of all of the Patents that are the subject of Enforcements against the Initial Targets;  evidence indicating that there may be a substantial reduction in the amount of Enforcement Proceeds (for example, without limitation, evidence that the quantity of infringing products is substantially less than anticipated and/or settlement offer(s) by 
		

		 

		

			7

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

		Company are less than anticipated); and/or where Attorney opines that there is less than a [*] chance of success on the merits;  provided that Funder has attempted but was unable to negotiate in good faith a consensual termination under Section 4.2.4 for not less than thirty (30) days;
		

		
			 
		

		
			4.2.2.The Company has failed to perform its material obligations hereunder in all material respects;  
		

		
			 
		

		
			4.2.3.There has been a material breach by Company of any of its material covenants, undertakings, representations or warranties herein; or
		

		
			 
		

		
			4.2.4.The Company consents to such termination.
		

		
			 
		

		
			4.3.If this Agreement is terminated by the Company pursuant to Section 4.1, notwithstanding anything in this Agreement to the contrary (including Schedule A), the Company will only have the obligation to pay to the Funder [*] percent [*] of Enforcement Proceeds received after the date of such termination and/or the Holdover Amount in accordance with the Holdover Instructions, until Funder has received on a cumulative basis (from the aggregate of the Enforcement Proceeds from Initial Targets, the Enforcement Proceeds from [*], Enforcement Proceeds from the Existing Litigations, and Subsequent Enforcement Proceeds), [*] percent [*] of the Reimbursement Amount, and the Company will have no obligation to pay Funder any amounts in excess of such amount.    [*]
		

		
			 
		

		
			4.4.If this Agreement is terminated by Funder pursuant to Section 4.2.1, the Company will only have the obligation to pay the Funder Enforcement Proceeds in accordance with Schedule A received after the date of such termination and/or the Holdover Amount in accordance with the Holdover Instructions,  except that the respective Multiple set forth in Schedule A shall otherwise be limited to [*] the Released Funding. [*]
		

		
			 
		

		
			4.5.If this Agreement is terminated by Funder pursuant to Section 4.2.2 or Section 4.2.3, the Company will not be released from its obligation to pay to the Funder the Funder’s Compensation, as provided by this Agreement.
		

		
			 
		

		
			4.6.If this Agreement is terminated by Funder pursuant to Section 4.2.4, notwithstanding anything in this Agreement to the contrary (including Schedule A), the Company’s obligation to pay the Funder’s Compensation shall terminate and any amounts to be paid to Funder by the Company will be negotiated in good faith by the Parties.
		

		
			 
		

		
			4.7.The rights of the Parties hereunder are without prejudice to any other rights that it might have at law to terminate this Agreement.  Any delay by a Party in exercising its rights to terminate this Agreement shall not constitute a waiver thereof.
		

		 

		

			8

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

		
			 
		

		
			5.BOOKS OF ACCOUNT AND TAXES 
		

		
			 
		

		
			5.1.BOOKS OF ACCOUNT. The Funder shall maintain an accounting of Released Funding and each Party shall have access thereto at all reasonable times.
		

		
			 
		

		
			5.2.TAX OPTIMIZATION.  The Parties shall attempt, in good faith, to structure the Enforcement Proceeds from Initial Targets in the most tax-efficient manner practicable so that there are no unnecessary deductions or withholdings, and will consider, in good faith, reasonable tax efficient structures for payment of such Enforcement Proceeds.  Funder and Company hereby agree that their respective tax counsel and/or advisors (if applicable) shall consult with each other in order to implement a tax efficient structure. 
		

		
			 
		

		
			6.[INTENTIONALLY OMITTED]
		

		
			 
		

		
			7.ADVERSE COSTS
		

		
			 
		

		
			8.1Company shall indemnify, hold harmless and defend (collectively “indemnify” and “indemnification”) Funder and its affiliates from and against all claims, demands, actions, suits, damages, liabilities, losses, settlements, judgments, costs and expenses (including but not limited to reasonable attorney’s fees and costs), whether or not involving a third party claim, which arise out of or relate to any Excluded Expense and/or Adverse Cost.
		

		
			 
		

		
			8.2Notwithstanding the foregoing, the Parties understand that the Company intends to obtain Insurance from an Insurer to protect against Company’s Adverse Costs liability and the Parties agree to cooperate in good faith to effect the payment of Insurance premiums and other Insurance costs and expenses, if any.
		

		
			 
		

		
			8.3The Company undertakes to the Funder that it will, and it will procure that its officers, employees and agents will, comply with, and will instruct the Attorney to ensure that they are fully aware of, all terms and conditions of the Insurance, so that the making of any payment under the Insurance is not prejudiced by a failure of the part of the Company or the Attorney to comply with the terms thereof.  In particular, the Company and the Attorney will keep the Funder and, where applicable, the Insurer, fully informed of developments during the course of the Enforcements involving Initial Targets and provide the Funder, and where applicable the Insurer, with all necessary information pursuant to the terms and conditions of the Insurance in each case, to the extent the Attorneys may do so without waiving privilege. Subject to any contrary order of a relevant court, nothing in this Agreement shall confer any liability on the Funder for any Adverse Costs to the extent that coverage under the Insurance is denied as a result of a breach of duty owed to the Insurer by the Company and/or breach by the Company of the terms of the Insurance or 
		
		
 

		

			9

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

		any other withdrawal of coverage for whatever reason and the Company hereby indemnifies the Funder against any such liability in relation to such Adverse Costs.

		
		
			 
		

		
			8.[*] 
		

		
			 
		

		
			8.1.[*]    
		

		
			 
		

		
			9.COVENANTS OF THE COMPANY
		

		
			 
		

		
			Company hereby covenants that it shall:
		

		
			 
		

		
			9.1.Instruct the Attorneys to conduct the  Enforcement involving Initial Targets in accordance with [*] applicable in the relevant courts and to comply with any judgment, order or award made in such Enforcement or Appeal;
		

		
			 
		

		
			9.2.Instruct the Attorneys to provide Funder with reports on the Enforcements and any Appeals involving Initial Targets to the extent the Attorneys may do so without waiving privilege, in a form and substance to be agreed among the Funder, the Attorneys and the Company;
		

		
			 
		

		
			9.3.Instruct the Attorneys to provide the Funder, insofar as is reasonably practicable and appropriate, [*], prior to the commencement of any Enforcement involving Initial Targets, along with [*];
		

		
			 
		

		
			9.4.Through instructions to the Attorneys to keep the Funder promptly informed of any significant developments in all Enforcements and Appeals involving Initial Targets (including any settlement discussions, any offers received and any information, evidence or advice coming to the attention of the Company or the Attorneys which may be material either to the prospects of success of the claim or of enforcing any judgment or award), in each case, to the extent the Attorneys may do so without waiving privilege;  
		

		
			 
		

		
			9.5.Authorize the Attorneys to provide all information requested by the Funder to the extent it may do so without waiving privilege, breaching any court order, confidentiality agreements or work product protections;
		

		
			 
		

		
			9.6.Consider the legal advice of the Attorneys at all appropriate junctures, including whether it would be advisable to mediate, arbitrate, or make or accept any offer to settle any Enforcement or Appeal involving an Initial Target;
		

		
			 
		

		
			9.7.Cooperate fully during each Enforcement and any Appeals involving an Initial Target with, and promptly provide such instructions and assistance to, the Attorneys as they may require to conduct such Enforcement or Appeal, including attending at court and giving oral evidence (if required), providing or procuring the provision of documents in the possession or control of the 
		
		
 

		

			10

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

		Company or any subsidiaries, associated companies or agents of the Company, and, insofar as advised by the Attorneys, making itself and its personnel available, and/or providing access to witnesses, for the purpose of preparing witness statements and ensuring or procuring the attendance of those witnesses at trial to give evidence on Company’s behalf; 

		
		
			 
		

		
			9.8.Give reasonable notice of and permit Funder, where reasonably practicable and provided that, in the sole opinion of Attorney that no privilege or confidentiality issues are implicated, to [*];
		

		
			 
		

		
			9.9.See to it that all patent maintenance fees and expenses necessary to maintain the Patents that are the subject of Enforcements against the Initial Targets in good standing are timely paid; 
		

		
			 
		

		
			9.10.If the Funder requires any advice given by the Attorneys to the Company in respect of any Enforcement or Appeal involving Initial Targets to be confirmed, Company will instruct the Attorneys to provide a written opinion to Company on such advice with a copy to Funder, with the costs of such written opinion to be borne by Funder and included in the Committed Capital;  
		

		
			 
		

		
			9.11.Keep the Patents that are the subject of Enforcements against the Initial Targets in the Company and not move them to another entity without the prior written consent of the Funder;
		

		
			 
		

		
			9.12.Cooperate with the Funder in all matters pertaining to the Enforcements and any Appeals involving Initial Targets, and devote sufficient time and attention as is reasonably necessary to their successful prosecution and conclusion;
		

		
			 
		

		
			9.13.Not sell, pledge or exchange any of the Enforcement Proceeds, except as otherwise provided in this Agreement;
		

		
			 
		

		
			9.14.Do nothing that is reasonably likely to have a material adverse impact upon any Enforcement or Appeal involving Initial Targets or with respect to Enforcement Proceeds; and 
		

		
			 
		

		
			9.15.If the Attorney should withdraw from their representation of Company for any reason, then Company will be at liberty to replace the Attorney with other suitable legal advisors, but only if the Funder approves the identity of the new legal advisors and fee arrangement (such approval not to be unreasonably withheld or delayed). 
		

		
			 
		

		
			10.REPRESENTATIONS AND WARRANTIES OF THE COMPANY
		

		
			 
		

		
			The Company hereby represents and warrants to Funder that:
		

		
			 
		

		
			10.1.Company is duly organized, validly existing and in good standing under the laws of its domicile.  Company has all necessary corporate power and 
		
		
 

		

			11

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

		authority to execute and deliver this Agreement and to perform its obligations hereunder and thereunder.  This Agreement constitute valid and legally binding obligations of Company, enforceable against Company in accordance with their terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium, arrangement or other similar applicable law or equitable principles relating to or limiting creditors’ rights generally. Company has all requisite corporate power and authority to carry on its business as now being conducted as it relates to the Patents that are the subject of Enforcements against the Initial Targets

		
		
			 
		

		
			10.2. No consent, waiver, approval, order or authorization of, or registration, declaration or filing with, or notice to any governmental authority is required by, or with respect to, Company or the Patents that are the subject of Enforcements against the Initial Targets in connection with the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby, except for filings and disclosures required under the Securities Laws. 
		

		
			 
		

		
			Company has good and marketable title to all of the Patents that are the subject of Enforcements against the Initial Targets.  Company holds all of the Patents that are the subject of Enforcements against the Initial Targets free and clear of all liens and/or encumbrances. There is no action, suit, audit, claim, proceeding or investigation pending or, to Company’s knowledge, threatened, against Company or any of its affiliates before any governmental authority, against, relating to or affecting the Patents that are the subject of Enforcements against the Initial Targets, or seeking to prevent Company’s performance of this Agreement or the transactions contemplated hereby, including without limitation any attacks, including interferences, oppositions, requests for reexamination, or other attacks or challenges to the validity or enforceability of, as applicable, the Patents that are the subject of Enforcements against the Initial Targets, or as to Company’s use or ownership of the Patents that are the subject of Enforcements against the Initial Targets (except as otherwise disclosed to the Funder).  Company has taken all steps reasonably necessary or appropriate (including, entering into written confidentiality and nondisclosure agreements with officers, directors, subcontractors, employees, licensees and customers) to safeguard and maintain the secrecy and confidentiality of any trade secrets included in the Patents that are the subject of Enforcements against the Initial Targets.  Neither Company nor, to Company’s knowledge, any inventor or other individual connected in any way to the prosecution of the Patents that are the subject of Enforcements against the Initial Targets have engaged in any conduct, or omitted to perform any necessary act, the result of which would invalidate any of such Patents or hinder their enforcement, including, without limitation, failure to name the proper inventors or failing to disclose material information to the U.S. Patent Office. 
		

		
			 
		

		
			10.3.The execution and delivery of this Agreement by Company does not and the consummation of the transactions contemplated hereby by Company will not 
		
		
 

		

			12

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

		(i) violate any provision of the Certificate of Incorporation, Bylaws or similar governance documents of or applicable to Company, (ii) result in a breach (or in any event which, with notice or lapse of time or both, would constitute a breach) of any term or provision of, or constitute a default under, any material agreement or material arrangement to which Company or any affiliate is a party or any agreement or arrangement by which the Patents that are the subject of Enforcements against the Initial Targets are bound, (iii) result in the creation of any lien on the Patents that are the subject of Enforcements against the Initial Targets, or (iv) violate any applicable law or any judgment, decree, order, regulation or rule of any governmental authority by which Company (or any of its subsidiaries, if applicable) is bound or subject.

		
		
			 
		

		
			10.4.No funding, facilities, or personnel of any governmental authority or educational institution were used, directly or indirectly, to develop or create, in whole or in part, any of the Patents that are the subject of Enforcements against the Initial Targets.  Company has not made any submission or suggestion to, and is not subject to any agreement with, any standards bodies or other entities that would obligate the Company to grant licenses to or otherwise impair its control of the Patents that are the subject of Enforcements against the Initial Targets.
		

		
			 
		

		
			10.5.Company shall not become insolvent, as the term is used in applicable law related to state and federal fraudulent conveyance or transfer or Bankruptcy law.
		

		
			 
		

		
			10.6.No transfer of property is being made and no obligation is being incurred in connection with the transactions contemplated by this Agreement with the intent to hinder, delay or defraud any present or future creditors of Company or any of its affiliates.  
		

		
			 
		

		
			10.7.Except as otherwise expressly set forth in this Agreement, Company acknowledges that Funder does not assume any contract, debt, liability, tax, employee liability, warranty or other obligation of any nature, fixed, contingent, known or unknown, of Company or any of its affiliates or former affiliates.
		

		
			 
		

		
			10.8.Company has been advised by independent legal counsel with regard to the consequences of entering into this Agreement.
		

		
			 
		

		
			10.9.Company hereby warrants to the Funder that it is not (and none of its officers, employees or agents is) aware of any information in its or their possession which is, or might reasonably be expected to be, materially relevant either to the outcome of any Enforcement involving Initial Targets or to the recoverability of Enforcement Proceeds from Initial Targets (“Relevant Information”) and which has not been disclosed to Funder.  At the same time, Company warrants to the Funder that, other than as has been disclosed to the Funder before this Agreement has been entered into, there has been no 
		
		
 

		

			13

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

		material change to the Relevant Information provided to the Funder during the due diligence process conducted by or on behalf of the Funder.

		
		
			 
		

		
			The foregoing representations and warranties shall be deemed made on and as of the Effective Date and repeated, throughout the duration of this Agreement, on each day funds are released by the Funder pursuant to 2.2.3.  If, after the date of this Agreement, Company or any of its officers, employees, agents or other affiliates becomes aware of any Relevant Information, Company shall instruct the Attorneys immediately to inform Funder of such information to the extent the Attorneys may do so without waiving privilege.
		

		
			 
		

		
			11.CONFIDENTIALITY; INFORMATION AND PRIVILEGE
		

		
			 
		

		
			11.1.Each Party shall use its best efforts:
		

		
			 
		

		
			11.1.1.To ensure that any “Confidential Information, defined as being any information in whatever form which may be imparted in confidence or be of a confidential nature, including without limitation the existence and terms of this Agreement and any information relating to the business, plans, commercial objectives or internal affairs of any the other Party and all notes, analysis, compilations, reports forecasts, data etc. prepared by either Party or its Disclosees (defined below) that contain, are based on or otherwise reflect in whole or in part the foregoing, is only made available to such of such other Party’s senior employees and officers and such of such other party’s advisers (“the Disclosees”) as need to have access to it for the purpose of this Agreement and who are subject to confidentiality duties or other obligations that are no less restrictive than the terms and conditions in this Section 11;
		

		
			 
		

		
			11.1.2.Without prejudice to any duty that arises in law or by reason of the relationship created by virtue of this Agreement, to keep (and ensure that the Disclosees keep) confidential all Confidential Information and not disclose (and ensure that none of the Disclosees discloses) any Confidential Information to any person, firm or company or part with possession of any Confidential Information;
		

		
			 
		

		
			11.1.3.To only disclose (and ensure that Disclosees only disclose) Confidential Information either that the other Party to whom such Confidential Information belongs has by prior consent approved for disclosure, or is disclosed to attorneys, experts, consultants or agents in furtherance of the Enforcement involving Initial Targets,  or subject to Section 11.3,  that a Disclosee is required by law to disclose;
		

		
			 
		

		
			11.1.4.To not make use of (and ensure that Disclosees not make use of) any Confidential Information except in the interests of the other Party for 
		
		
 

		

			14

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

		the purposes of providing (and receiving) the party’s common objectives; and

		
		
			 
		

		
			11.2.Immediately following termination of this Agreement or on written demand from the other Party, forthwith either return (and procure the return by the Disclosees of) Confidential Information or (if the other Party has given its prior consent to the destruction thereof) produce a declaration signed by an authorized officer of the other Party certifying that so far as that  Party is aware, after reasonable investigation, such Confidential Information has been destroyed by that other Party and/or the Disclosees, provided that that Party may retain copies of such information as may be properly required for legal and/or regulatory reasons subject to full details of such information being supplied to the other Party, provided that notwithstanding the return or destruction of the Confidential Information, the Party receiving the Confidential Information (“Receiving Party”) and its Disclosees will be bound by their confidentiality and other obligations under this Section 11.
		

		
			 
		

		
			11.3.In the event that the Receiving Party or its Disclosees is requested or required, by oral questions, interrogatories, requests for information or documents in legal proceedings, subpoena, civil investigative demand or other similar process, to disclose any of the Confidential Information, the Receiving Party shall provide the other Party with prompt written notice of any such request or requirement so that, if practical, the other Party may seek a protective order or other appropriate remedy and/or waive compliance with the provisions of this Agreement. If, in the absence of a protective order or other remedy or the receipt of a waiver, the Receiving Party receives advice of counsel that it or its Disclosees is nonetheless legally compelled to disclose the Confidential Information or else stand liable for contempt or suffer other censure or penalty, the Receiving Party or its Disclosees may, disclose only that portion of the Confidential Information which such counsel advises is legally required to be disclosed, provided that the Receiving Party exercises its reasonable efforts to preserve the confidentiality of the Confidential Information, including, without limitation, by cooperating with the other Party and its representatives to obtain an appropriate protective order or other reliable assurance that confidential treatment will be accorded the Confidential Information.
		

		
			 
		

		
			11.4.Each Party shall be responsible for any breach of this agreement by its Disclosees and shall, at its sole expense, use its best efforts to restrain its Disclosees from prohibited or unauthorized disclosure or use of the Confidential Information of the other Party.
		

		
			 
		

		
			11.5.In the event that the Agreement is terminated, the obligations set out in Sections 11.1–11.5 shall, remain in full force and effect until each applicable party releases the other(s) from such obligations, except that the foregoing clause shall not apply to Confidential Information that is in the public domain other than as a consequence of a breach of the above provisions.
		

		 

		

			15

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

		
			 
		

		
			11.6.The Parties agree that they have a “common legal interest” in the Enforcements involving Initial Targets, this Agreement and any discussion, evaluation and negotiation and other communications and exchanges of information relating thereto. Therefore, insofar as any privileged communication is shared between the parties, it will be subject to a common interest privilege. The parties agree and intend that any material or information exchanged in pursuit of this common interest shall at all times remain subject to all applicable privileges and protections from disclosure, including the attorney-client privilege, litigation privilege, common interest privilege, work-product immunity doctrine and any applicable rules of professional secrecy in any jurisdiction. It is the express intent of Company and Funder and their respective affiliates to preserve intact to the fullest extent applicable, and not to waive by virtue of this Agreement, any action contemplated by this Agreement, or otherwise, in whole or in part, any and all privileges and immunities otherwise attaching to the exchange of material or information pursuant to this Agreement. 
		

		
			 
		

		
			12.PRESS RELEASES; SECURITIES LAWS COMPLIANCE
		

		
			 
		

		
			12.1.Notwithstanding anything in this Agreement to the contrary, including the provisions of Section 11, the Parties agree that the Company may make such filings and disclosures of Confidential Information as it determines, upon advice of counsel, are required by Securities Laws, provided that the Company will use reasonable efforts to seek confidential treatment for Confidential Information that the Company determines, upon advice of counsel, is permitted to be obtained under the Securities Laws.
		

		
			 
		

		
			12.2.The Parties agree that promptly following the Effective Date the Company will issue a press release and within four (4) business days following the of the Effective Date, Company will file with the Securities and Exchange Commission a Current Report on  Form 8-K disclosing the execution and delivery of this Agreement and other disclosures required by the Securities Laws.  The Company will provide copies of the press release and Form 8-K to Funder for Funder’s review in advance of their issuance/filing.
		

		
			 
		

		
			13.LIMITATION OF LIABILITY
		

		
			 
		

		
			13.1.Company agrees that there shall be no liability of the Funder under this Agreement, or related to its activities in connection with this Agreement, except for gross negligence, wilful misconduct, fraud or reckless activity amounting to fraud and/or a breach of the provisions of Section 2.2, as qualified by Section 4.2, that has a material adverse effect on any Enforcement involving Initial Targets or Company. This limitation on liability is absolute and excludes liability, by way of illustration and not limitation, for negligence, and for any damages that may constitute compensatory damages, lost profit, or punitive damages. This limitation on liability extends to the Funder and its 
		
		
 

		

			16

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

		representatives, affiliates, agents, officers, directors and employees and their successors and assigns.

		
		
			 
		

		
			13.2.Funder agrees that there shall be no liability of Company under this Agreement, or related activities in connection with this Agreement, except for gross negligence, wilful misconduct, fraud or reckless activity amounting to fraud and/or for any failure to pay to Funder any Enforcement Proceeds to which the Funder is otherwise entitled under this Agreement, or under Section 2.1. This limitation on liability is absolute and excludes liability, by way of illustration and not limitation, for negligence, and for any damages that may constitute compensatory damages, lost profit, or punitive damages. This limitation on liability extends to Company and its representatives, affiliates, agents, officers, directors and employees and their successors and assigns.
		

		
			 
		

		
			13.3.Funder agrees and acknowledges that Funder’s Compensation shall be paid by the Company solely from the Enforcement Proceeds and Funder will have no security interest in any asset of Company. 
		

		
			 
		

		
			14.TRANSFERABLIITY 
		

		
			 
		

		
			14.1.This Agreement may not be assigned by either Party without the prior written consent of the other Party.
		

		
			 
		

		
			15.MISCELLANEOUS
		

		
			 
		

		
			15.1.NOTICES. Except as otherwise specifically provided in this Agreement, any notice, payment, demand or communication required or permitted to be given by any provision of this Agreement shall be duly given if delivered in writing personally to the person to whom it is directed, or if sent by post, email or fax, to a Party at its address set forth in Schedule A or to such other address as the Party may from time to time specify by written notice. Any such notice shall be deemed to be given, if given personally, as of the date delivered; if given by email or fax, as of the date sent; or if posted, as of the date on which the same was deposited in the United States mail, postage prepaid, addressed and sent as aforesaid.
		

		
			 
		

		
			15.2.SECTION CAPTIONS. Section and other captions contained in this Agreement are for reference purposes only and are in no way intended to describe, interpret, define or limit the scope, extent, or intent of this Agreement or any provision hereof.  
		

		
			 
		

		
			15.3.SEVERABILITY. Every provision of this Agreement is intended to be severable. If any term or provision of this Agreement is illegal or invalid for any reason whatsoever, such illegality or invalidity shall not affect the validity of the remainder of this Agreement.  
		

		
			 
		

		 

		

			17

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

		
			15.4.AMENDMENTS. This Agreement may only be amended with the written consent of both Parties.  
		

		
			 
		

		
			15.5.GOVERNING LAW. The laws of the State of Delaware shall govern the validity of this Agreement, the construction of its terms and the interpretation of the rights and duties of the parties hereto.  
		

		
			 
		

		
			15.6.COUNTERPART EXECUTION. This Agreement may be executed in one or more counterparts all of which together shall constitute one and the same Agreement.  
		

		
			 
		

		
			15.7.PARTIES IN INTEREST. This Agreement shall be binding upon the parties hereto and their successors and assigns.  
		

		
			 
		

		
			15.8.CONSTRUCTION OF PRONOUNS. The feminine or neuter of the words “he”, “his” and “him” used herein shall be automatically deemed to have been substituted for such words where appropriate to the particular Party executing this Agreement.  
		

		
			 
		

		
			15.9.INTEGRATED AGREEMENT. This Agreement, including its Schedules and Appendices, constitutes the entire understanding and agreement among the parties hereto with respect to the subject matter hereof, and there are no agreements, understandings, restrictions, representations or warranties among the parties other than those set forth herein or herein provided for. 
		

		
			 
		

		
			15.10.DISPUTE RESOLUTION.  If a dispute arises under this Agreement which the parties cannot resolve within 15 business days, the dispute may be referred by any Party to a mutually acceptable and neutral mediator who will be jointly instructed and who will conduct a mediation between the Parties. If the parties fail to agree upon a neutral mediator within 30 business days after a Party notifies the other of the need for mediation,  or  if the Parties fail in mediation to resolve the dispute, the parties agree to submit such dispute to binding arbitration administered by the American Arbitration Association in accordance with its Commercial Arbitration Rules (including the Optional Rules for Emergency Measures of Protection) in New York City, New York, and judgment on the award rendered by the arbitrator(s) may be entered in any court having jurisdiction thereof.
		

		
			 
		

		
			15.11.NO PRACTICE OF LAW.  Neither Party is a law firm and neither it nor its Affiliates are engaged in the practice of law or any other professional activity such as accounting.  Each Party agrees that it has not relied and will not rely on the other Party or the other Party’s officers, directors employees or affiliates for legal, accounting or other professional advice and represents that it has received independent legal advice in connection with the transactions contemplated hereby. Nothing in this Agreement shall be construed to give rise to or create a fiduciary, lawyer-client, agency or other relationship between the Parties or between either Party and any director, partner, officer, 
		
		
 

		

			18

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

		employee or agent of the other Party or between their counsel, notwithstanding that information, observations or opinions may be exchanged between them.

		
		
			 
		

		
			15.12.CONTROL OF ENFORCEMENTS. Although the Funder will be responsible for funding Enforcements  involving Initial Targets pursuant to this Agreement, the Company will instruct the Attorneys and the Company, not the Funder, will have control of such Enforcements.
		

		
			 
		

		
			15.13.RELATIONSHIP OF FUNDER AND COMPANY.  The Company and the Funder are independent actors. This Agreement does not create any joint venture, partnership, agency relationship or any other type of affiliation.
		

		
			 
		

		
			15.14.SOPHISTICATED PARTIES.  The Parties each acknowledge, accept, warrant and represent that (i) they are sophisticated Parties represented at all relevant times during the negotiation and execution of this Agreement by counsel of their choice, and that they have executed this Agreement with the consent and on the advice of such independent legal counsel, and (ii) they and their counsel have determined through independent investigation, extensive due diligence, and robust, arms-length negotiation that the terms of this Agreement shall exclusively embody and govern the subject matter of this Agreement.
		

		
			 
		

		
			 
		

		
			 
		

		
			[SIGNATURE PAGE FOLLOWS]
		

		

		

		 

		

			19

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

		IN WITNESS WHEREOF, the undersigned have hereunto set their hands as of the day and year first above written.
		

		
			 
		

		
			ParkerVision, Inc.  (as “Company”)
		

		
			 
		

		
			By: ______________________________
		

		
			     Name:
		

		
			     Title:
		

		
			 
		

		
			1624 PV LLC (as “Funder”)
		

		
			 
		

		
			By: ______________________________
		

		
			     Name:
		

		
			     Title:
		

		
			 
		

		
			 
		

		
			 
		

		

		

		 

		

			20

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

		SCHEDULE A
		

		
			 
		

			
					
						 

					
					
						 

				
	
					
						PATENTS

					
					
						All patents owned by Company including any additional reissue, re-examination, continuations, continuations-in-part, applications, patents pending and/or counterparts.

				
	
					
						ENFORCEMENT PLAN

					
					
						Company shall pursue Enforcement (through litigation or otherwise) against one of the Initial Targets [*].

					
						Subject to the mutual agreement of the Parties, Company may expand the Enforcement through [*].  

				
	
					
						INITIAL TARGETS

					
					
						[*] as agreed upon by Company and Funder.

				
	
					
						ATTORNEYS

					
					
						[*]    

				
	
					
						COMMITTED CAPITAL

					
					
						Committed Capital shall be $7,000,000 in the aggregate.  

					
						The Committed Capital may be reduced upon [*] and where the Parties consent to such adjustment.

				
	
					
						REIMBURSEMENT AMOUNT

					
					
						An amount equal to the Released Funding.

				

		 

		

			21

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

			
					
						FUNDER’S COMPENSATION

					
					
						Funder shall be entitled to receive, and Company agrees to pay or procure payment (in either case as soon as reasonably practicable) to Funder of, the following amounts of Enforcement Proceeds from Initial Targets (“Funder’s Compensation”) in accordance with priorities identified in Appendix A and the following formula, unless Initial Target has been identified as a [*] (as defined below) in which case the [*] Compensation shall apply:

					
						1. First, [*] of all such Enforcement Proceeds until Funder has received the entire Reimbursement Amount; and 

					
						2.   Second, [*] of all remaining Enforcement Proceeds from Initial Targets (net of the Reimbursement Amount and Priority payments) until Funder has received (on a cumulative basis from the aggregate of the Enforcement Proceeds from [*]), depending on the applicable threshold below, the corresponding multiple of the Reimbursement Amount:

					
						“Target Amount” means an amount of Funder’s Compensation received by Funder in accordance with the foregoing formula equal to the greater of (a) [*] times the Reimbursement Amount or (b) [*], provided however that Company may pre-pay the difference between [*] and the Funder’s Compensation already received by Funder in order to attain the Target Amount.

				
	
					
						 

					
					
						THRESHOLD

					
					
						MULTIPLE

				
	
					
						 

					
					
						If Funder receives the full Target Amount (as defined below) on or before the [*] anniversary of the first Released Funding:

					
					
						[*] times the Reimbursement Amount.

				
	
					
						 

					
					
						If Funder receives the full Target Amount after the [*] anniversary of the Effective Date but on or before [*] anniversary of the first Released Funding:

					
					
						[*] times the Reimbursement Amount.

				
	
					
						 

					
					
						If Funder receives the full Target Amount after the [*] anniversary of the first Released Funding:

					
					
						[*] times the Reimbursement Amount.

				

		 

		

			22

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

			
					
						 

					
					
						“Target Amount” means an amount of Funder’s Compensation received by Funder in accordance with the foregoing formula equal to the greater of (a) [*] times the Reimbursement Amount or (b) [*], provided however that Company may pre-pay the difference between [*] and the Funder’s Compensation already received by Funder in order to attain the Target Amount.

				
	
					
						[*]

					
					
						[*]

					
					
						 

				

		
			 
		

		 

		

			23

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

			
					
						SUBSEQUENT ENFORCEMENTS 

					
					
						Until Funder has been paid the entire Funder’s Compensation with respect to the Initial Targets, Funder shall have the first right, but not the obligation (“Negotiation Right”), in its sole discretion, to negotiate the provision of additional contingent litigation funding to the Company (“Subsequent Enforcements Funding”) for use in subsequent Enforcements against Targets other than the Existing Enforcement or the Enforcement against Initial Targets (“Subsequent Enforcements”).  Before entering into negotiations for Subsequent Enforcements Funding with any third party, the Company shall notify Funder in writing that it may pursue Subsequent Enforcements Funding and Funder shall have ten (10) days from receipt of such notice to provide the Company with written notice that it desires to enter into good faith negotiations with the Company regarding such funding (“Notice”).  If Funder does not provide the Notice within such ten (10) day period, then the Company shall have no further obligation with respect to the Negotiation Right and shall be free to negotiate and obtain Subsequent Enforcements Funding with any third party.  If the Negotiation Right is properly exercised, then the Parties will negotiate exclusively, reasonably and in good faith concerning Subsequent Enforcements Funding for a period of fifteen (15) days following the Company’s receipt of the Notice.  If the Parties do not execute and deliver an agreement with respect to Subsequent Enforcements Funding within such fifteen (15) day period, then the Company shall have no further obligation with respect to the Negotiation Right and shall be free to negotiate and obtain Subsequent Enforcements Funding with any third party. 

					
						Where Company does not request contingent litigation financing for a Subsequent Enforcement and Funder does not, as a result, fund a Subsequent Enforcement, Funder shall nonetheless be entitled to participate in the gross proceeds in excess of [*] received by the Company from each Subsequent Enforcement (“Subsequent Enforcement Proceeds”) using the same formula as with respect to the Funder’s Compensation (as set forth above) until Funder has received the entire Funder’s Compensation with respect to the Initial Targets on a cumulative basis from the aggregate of the Enforcement Proceeds and/or Subsequent Enforcement Proceeds. [*]   

					
						Where Company requests contingent litigation financing for a Subsequent Enforcement but Funder declines to provide such financing, and where Company receives in excess of [*]of additional contingent litigation financing from another third-party funder (an “Other Funder”), Funder shall receive [*] of such Subsequent Enforcement Proceeds until Funder has received (on a cumulative basis from the aggregate of the Enforcement Proceeds [*]) its Reimbursement, plus:

				

		 

		

			24

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

			
					
						 

					
					
						THRESHOLD

					
					
						MULTIPLE

				
	
					
						 

					
					
						If Funder Receives the full Target Amount on or before the [*] anniversary of the first Released Funding.

					
					
						[*] times the Released Funding.

				
	
					
						 

					
					
						If Funder receives the full Target Amount after the [*] anniversary of the Effective Date, but on or before the [*] anniversary of the first Released Funding.

					
					
						[*] times the Released Funding.

				
	
					
						 

					
					
						If Funder receives the full Target Amount after the [*] anniversary of the first Released Funding.

					
					
						[*] times the Released Funding.

				
	
					
						 

					
					
						[*]

					
					
						 

				
	
					
						EXISTING LITIGATIONS

					
					
						Funder shall be entitled to participate in Enforcement Proceeds from existing Litigations (“Existing Litigations”) as follows:

					
						 

					
						First, [*] of Enforcement Proceeds from Existing Litigations until Funder has received, on a cumulative basis from the aggregate of the Enforcement Proceeds [*], the Released Funding;

					
						 

					
						Second, [*] of Enforcement Proceeds from Existing Litigations until Funder has received (on a cumulative basis from the aggregate of the Enforcement Proceeds [*]):

					
						 

				
	
					
						 

					
					
						Timing

					
					
						Multiple

				
	
					
						 

					
					
						If Funder Receives the full Target Amount on or before the [*] anniversary of the first Released Funding.

					
					
						[*] times the Released Funding.

				
	
					
						 

					
					
						If Funder Receives the full Target Amount beyond the [*] anniversary of the Effective Date, but before the [*] anniversary of the first Released Funding.

					
					
						[*] times the Released Funding.

				
	
					
						 

					
					
						If Funder Receives the full Target Amount beyond the [*] anniversary of the first Released Funding.

					
					
						[*] times the Released Funding.

				

		 

		

			25

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

			
					
						 

					
					
						If the Company obtains any contingent litigation funding from an Existing Litigation Funder with respect to Existing Litigations, [*].

				
	
					
						HOLDOVER

					
					
						Upon each receipt of Enforcement Proceeds from an Initial Target, Company shall deposit with Holdover Agent an amount equal to the difference between Funder’s Compensation as of such receipt of such Enforcement Proceeds and Funder’s Compensation if Released Funding had been 100% of Committed Capital (as adjusted pursuant to Committed Capital above) and Timing had been beyond the [*] anniversary of the first Released Funding at the same amount of Enforcement Proceeds (the “Holdover”).

					
						The Holdover shall be deposited into a designated account to be held in escrow by a third-party fiduciary (“Holdover Agent”) and not distributed except as provided herein.

				

		 

		

			26

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

			
					
						HOLDOVER INSTRUCTIONS

					
					
						Funder shall update the Holdover calculation (i) upon receipt of Enforcement Proceeds from Initial Targets, including [*], (ii) prior to release of any Holdover amount to any party, and (iii) at the end of each calendar quarter, to update for the release of additional amounts under the Committed Capital, a reduction in Committed Capital pursuant to provisions above, and/or the definitive setting of Timing at less than [*] from the anniversary of the first Released Funding. The updated Holdover calculation shall specify any reductions in Holdover amount and instructions as to which party the reduction should be distributed to. Such Holdover calculation shall be certified by the Company and provided to the Holdover Agent upon update.

					
						The Holdover Agent shall release specified monies in Holdover when:

					
						i)A certified update is received by the Holdover Agent indicating a reduction in the Holdover amount, 

					
						ii)The Agreement is terminated by the Company pursuant to Section 4.1, at which point the Holdover Agent shall pay to the Funder the Holdover amount up to, on a cumulative basis, [*] percent [*] of Funder’s Reimbursement Amount and shall pay to the Company all any amounts in excess of Funder’ Reimbursement Amount.

					
						iii)The Agreement is terminated by Funder pursuant to Section 4.2.1, at which point the Holdover Agent shall pay to the Funder the Holdover amounts up to, on a cumulative basis, [*] the Reimbursement Amount and shall pay to the Company any Holdover amounts in excess of such amount.

					
						iv)The Agreement is terminated by the Funder pursuant to Sections 4.2.2 or 4.2.3, at which point the Holdover Agent shall pay to the Funder the Holdover amounts up to the total amount of the Funders Compensation and shall pay to the Company any Holdover amounts in excess of Funder’s Compensation.

					
						v)The Agreement is terminated by Funder pursuant to Section 4.2.4 and the Company and Funder provide mutual instructions to the Holdover Agent, at which time the Holdover Agent shall release Holdover amounts to the Funder and/or the Company in accordance with the mutual instructions.

				
	
					
						ADDRESS OF THE FUNDER

					
					
						1900 K Street, NW

					
						Suite 725

					
						Washington D.C. 20006

				

		 

		

			27

		

		

			 

		

 

		

			* CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

		

			
					
						ADDRESS OF THE COMPANY

					
					
						7915 Baymeadows Way

					
						Suite 400

					
						Jacksonville, FL  32256

				

		
			 
		

		 

		

			28Exhibit 10.20

		
			SUBSCRIPTION AGREEMENT
		

		
			This SUBSCRIPTION AGREEMENT (“Subscription Agreement”) is made and entered into on December 18, 2014, between ParkerVision, Inc., a Florida corporation (“Company”) and 1624 PV LLC, a Delaware limited liability company (“Investor”).
		

		
			The Company and Investor hereby agree as follows:
		

			
	
			
				 1.
			Subscription for Warrants. Investor hereby subscribes for and agrees to purchase from the Company warrants (each a “Warrant”) to purchase up to an aggregate of 5,652,174 shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), for a purchase price of $1,300,000 (“Purchase Price”).  At the Closing (defined below), the Company will issue to Investor three Warrants, each exercisable for up to 1,884,058 shares of Common Stock with an exercise price per share of $1.50, $2.50 and $3.50, respectively, under the terms and conditions set forth in the form of Warrant attached as Exhibit A hereto. 

			
	
			
				 2.
			Closing.    The closing of the purchase of the Warrants (the “Closing”) will occur on such date as shall be mutually agreed to by the Company and Investor, but in no event later than January 15, 2015.  At the Closing, Investor shall tender the full Purchase Price by wire transfer to the Company in accordance with instructions provided to Investor by the Company prior to the Closing and the Company shall deliver Warrant certificates to Investor.

			
	
			
				 3.
			Registration of Warrant Shares. The Company will use commercially reasonable efforts to: (a) file with the Securities and Exchange Commission (“Commission”) on or before the 60th day after Closing, a  registration statement covering the resale of all of the shares of Common Stock issuable upon exercise of the Warrants (“Warrant Shares”),  for an offering to be made on a continuous basis pursuant to Rule 415 promulgated by the Commission under the Securities Act of 1933, as amended (the “Securities Act”); (b) timely respond to the comments of the Commission to such registration statement; and (c) have such registration statement declared effective by the Commission as soon as practicable thereafter. The registration statement will be on Form S-3 (except if the Company is not then eligible to register for resale the Warrant Shares on Form S-3, in which case such registration shall be on another appropriate form). Investor shall timely provide the Company with any information regarding Investor and its affiliates that is required for the registration statement or as otherwise reasonably requested by the Company to meet its obligations under this Section 3 (“Investor Information”).

			
	
			
				 4.
			Investor Representations and Warranties.  Investor represents and warrants to the Company as follows:

			
	
			
				 4.1
			Accredited Investor.  Investor is an “accredited investor” as defined in Section 2(15) of the Securities Act, and Rule 501 promulgated thereunder. Investor understands that the Warrants are being issued to Investor without registration under the Securities Act in reliance upon the exemptions contained in Regulation D promulgated under the Securities Act (“Regulation D”) and applicable state securities laws.

			
	
			
				 4.2
			Obligations of the Company and the Investor.   The Company has no obligation to Investor with respect to the sale and purchase of the Warrants other than as set forth in this Subscription Agreement. Investor is aware that, except for any rescission rights that may be provided under applicable laws, Investor is not entitled to cancel, terminate or revoke this Subscription Agreement.  In order to induce the Company to issue and sell the Warrants to Investor,  Investor represents and warrants that the information relating to Investor stated herein is true and complete as of the date hereof and will be true and complete as of the date of the Closing.

		 

		

			 

		

		

			

		

 

			
	
			
				 4.3
			Information About the Company.    Investor has been given reasonable opportunity to meet with officers of the Company for the purpose of asking reasonable questions of such officers concerning the terms and conditions of the sale and issuance of the Warrants and the business and operations of the Company (including the risks faced by the Company in its business and risks related to Investor’s investment in the Company) and all such questions have been answered to Investor’s full satisfaction. Investor has also been given an opportunity to obtain any additional relevant information to the extent reasonably available to the Company. Investor has received all information regarding the Company that Investor has reasonably requested. Investor has read and reviewed the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 and the Company’s Quarterly Reports for its 2014 fiscal quarters.  Investor understands that there is no assurance as to the future performance of the Company. 

			
	
			
				 4.4
			No assurances; No General Solicitation.  Investor has received no representation or warranty from the Company or any of its officers, directors, employees or agents in respect of Investor’s investment in the Company. Investor is  not purchasing the Warrants as a result of or subsequent to: (a) any advertisement, article, notice or other communication published in any newspaper, magazine or similar media or broadcast over television, radio or the Internet; or (b) any seminar or meeting whose attendees have been invited by any general solicitation or general advertising.

			
	
			
				 4.5
			Speculative Investment.  Investor is aware that its purchase of Warrants is a speculative investment. Investor acknowledges that Investor can lose the entire amount of its investment in the Company.  Investor has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of an investment in the Warrants and has obtained, in its judgment, sufficient information from the Company to evaluate the merits and risks of an investment in the Company. Investor has not utilized any person as a  purchaser representative (as defined in Regulation D) in connection with evaluating such merits and risks and has relied solely upon its own investigation in making a decision to invest in the Company. Investor has been urged to seek independent advice from its professional advisors relating to the suitability of an investment in the Company in view of its overall financial needs and with respect to the legal and tax implications of such investment. Investor believes that the investment in the Company represented by its purchase of the Warrants is suitable for Investor based upon its investment objectives and financial needs, and Investor has adequate means for providing for its current financial needs and contingencies and has no need for liquidity with respect to its investment in the Company.

			
	
			
				 4.6
			Authority.   Investor has all necessary power and authority to enter into this Subscription Agreement and to consummate the transactions contemplated hereby. All action necessary to be taken by Investor to authorize the execution, delivery and performance of this Subscription Agreement has been duly and validly taken and this Subscription Agreement has been duly executed and delivered by Investor. Subject to the terms and conditions of this Subscription Agreement, this Subscription Agreement constitutes the valid and binding obligation of Investor, enforceable in accordance with its terms, except as enforceability may be limited by (a) applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer or similar laws of general application now or hereafter in effect affecting the rights and remedies of creditors and by general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity) and (b) the applicability of the federal and state securities laws and public policy as to the enforceability of the indemnification provisions of this Subscription Agreement.

			
	
			
				 4.7
			Restrictions on Transfer.  Investor understands that (a) the Warrants have not been registered under the Securities Act or the securities laws of any state in reliance on specific exemptions from registration and (b) the Warrants and the Warrant Shares cannot be resold, pledged, assigned or otherwise disposed of unless they are registered under the Securities Act and under applicable 
		

		 

		

			 

		

		

			

		

 

			securities laws of certain states, or an exemption from such registration is available. In addition, Investor understands that the Company is relying on Investor’s representations and agreements for the purpose of determining whether the sale and purchase of the Warrants meets the requirements of registration exemptions afforded by the Securities Act and certain state securities laws.  

			
	
			
				 4.8
			Investment Representation.  Investor is acquiring the Warrants for its own account for investment and not with a view to, or for sale in connection with, any subsequent distribution of the securities, nor with any present intention of selling or otherwise disposing of all or any part of the Warrants in violation of the federal securities laws.  

			
	
			
				 5.
			Company Representations and Warranties.  The Company hereby represents and warrants to the Investor that the Company has all necessary corporate power and authority to enter into this Subscription Agreement and to consummate the transactions contemplated hereby.  All corporate action necessary to be taken by the Company to authorize the execution, delivery and performance of this Subscription Agreement and all other agreements and instruments delivered by the Company in connection with the transactions contemplated hereby has been duly and validly taken and this Subscription Agreement has been duly executed and delivered by the Company. Subject to the terms and conditions of this Subscription Agreement, this Subscription Agreement constitutes the valid and binding obligation of the Company, enforceable in accordance with its terms, except as enforceability may be limited by (a) applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer or similar laws of general application now or hereafter in effect affecting the rights and remedies of creditors and by general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity) and (b) the applicability of the federal and state securities laws and public policy as to the enforceability of the indemnification provisions of this Subscription Agreement.  The sale by the Company of the Warrants does not conflict with the certificate of incorporation or bylaws of the Company or any material contract by which the Company or its property is bound, or any federal or state laws or regulations or decree, ruling or judgment of any United States or state court applicable to the Company or its property. The sale of the Warrants will not trigger any pre-emptive or, to the knowledge of the Company, other rights held by any party and no governmental or regulatory consent is required for the consummation of the transactions contemplated by this Subscription Agreement.

			
	
			
				 6.
			Indemnification.  Investor shall indemnify and hold harmless the Company and its officers, directors, stockholders, employees, agents, and attorneys against any and all losses, claims, demands, liabilities, and expenses (including reasonable legal or other expenses incurred by each such person in connection with defending or investigating any such claims or liabilities, whether or not resulting in any liability to such person or whether incurred by the indemnified party in any action or proceeding between the indemnitor and  indemnified party or between the indemnified party and any third party) to which any such indemnified party may become subject, insofar as such losses, claims, demands, liabilities and expenses (a) arise out of or are based upon any untrue statement or alleged untrue statement of a material fact made by Investor and contained herein or in the Investor Information or (b) arise out of or are based upon any breach by Investor of any representation, warranty, or agreement made by Investor contained herein.

			
	
			
				 7.
			Insider Trading Policy.  Investor acknowledges that Investor is an “Insider” as defined in the Company’s insider trading policy (as such policy is amended from time to time, the “ITP”) and will remain so as long as Investor is a lender to the Company or otherwise meets the definition of an Insider under the ITP. Investor will at all times comply with the requirements of the ITP.

			
	
			
				 8.
			Severability; Remedies.  In the event any parts of this Subscription Agreement are found to be void, the remaining provisions of this Subscription Agreement are nevertheless binding with the same effect as though the void parts were deleted.

		 

		

			 

		

		

			

		

 

			
	
			
				 9.
			Governing Law and Jurisdiction.  All questions concerning the construction, validity, enforcement and interpretation of this Subscription Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Subscription Agreement shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.

			
	
			
				 10.
			Counterparts.  This Subscription Agreement may be executed in one or more counterparts, each of which will be deemed an original but all of which together will constitute one and the same instrument. 

			
	
			
				 11.
			Benefit.  This Subscription Agreement is binding upon and inures to the benefit of the parties hereto and their respective heirs, executors, personal representatives, successors and assigns. 

			
	
			
				 12.
			Notices.  All notices and other communications under this Subscription Agreement must be in writing, and are sufficiently given if delivered to the addressees in person, by overnight courier service, or, if mailed, postage prepaid, by certified mail (return receipt requested), and will be effective three days after being placed in the mail if mailed, or upon receipt or refusal of receipt, if delivered personally or by courier or confirmed telecopy, in each case addressed to a party. All communications to Investor should be sent to the address on the signature page hereto.  All communications to the Company should be sent to: ParkerVision, Inc. 7915 Baymeadows Way, Suite 400, Jacksonville, Florida 32256, Attention: Chief Financial Officer. Each party may designate another address by notice to the other party.

			
	
			
				 13.
			Entire Agreement.  This Subscription Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior oral and written agreements between the parties hereto with respect to the subject matter hereof.  This Subscription Agreement may not be changed, waived, discharged, or terminated orally, but rather, only by a statement in writing signed by the party or parties against whom enforcement or the change, waiver, discharge or termination is sought.

			
	
			
				 14.
			Section Headings.  Section headings herein have been inserted for reference only and will not be deemed to limit or otherwise affect, in any matter, or be deemed to interpret in whole or in part, any of the terms or provisions of this Subscription Agreement.

			
	
			
				 15.
			Survival of Representations, Warranties and Agreements.  The representations and warranties contained herein shall be true and correct at the time made and as of the Closing Date (as if made as of such date). The representations, warranties and agreements contained herein will survive the delivery of, and the payment for, the Warrants.  

		
			 
		

		
			 
		

		
			[SIGNATURE PAGE FOLLOWS]
		

		
			 
		

		
			
		

		 

		

			 

		

		

			

		

 

		Signature Page to Subscription Agreement
		

		
			 
		

		
			 
		

		
			          1642 PV LLC
		

		
			 
		

		
			 
		

		
			          By: _________________
		

		
			                Name:
		

		
			                  Title:
		

		
			 
		

		
			          Date:  December 18, 2014
		

		
			 
		

		
			          Investor Address:_________________
		

		
			                                    _________________
		

		
			                                    _________________
		

		
			 
		

		
			 
		

		
			          EIN: _________________ 
		

		
			 
		

		
			 
		

			
					
						 

					
						 

					
						 

					
						 

					
						 

					
						 

					
						________________________________

					
						 

					
						 

					
						 

					
						December 18, 2014

					
						 

				
	
					
						 

					
						The foregoing subscription is accepted and the Company hereby agrees to be bound by its terms.

					
						 

					
						PARKERVISION, INC.

					
						 

					
						 

					
						 

					
						By: ____________________________________

					
						      Name:

					
						      Title:

					
						      

					
						Date:  December 18, 2014

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]